205 related articles for article (PubMed ID: 21989071)
21. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
Degtiar I
Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
[TBL] [Abstract][Full Text] [Related]
22. P4 Medicine versus Hippocrates.
Pulciani S; Di Lonardo A; Fagnani C; Taruscio D
Ann Ist Super Sanita; 2017; 53(3):185-191. PubMed ID: 28956796
[TBL] [Abstract][Full Text] [Related]
23. UK’s adopts systematic approach to personalised cancer medicine.
Fricker J
Mol Oncol; 2011 Jun; 5(3):217-9. PubMed ID: 21774109
[No Abstract] [Full Text] [Related]
24. The value proposition of molecular medicine.
Waldman SA; Terzic A
Clin Transl Sci; 2012 Feb; 5(1):108-10. PubMed ID: 22376267
[No Abstract] [Full Text] [Related]
25. Costs Cast Shadow on Optimism about Treatment.
Manag Care; 2016 Oct; 25(10):29. PubMed ID: 28121542
[TBL] [Abstract][Full Text] [Related]
26. Personalized Mammography Screening and Screening Adherence-A Simulation and Economic Evaluation.
Arnold M; Quante AS
Value Health; 2018 Jul; 21(7):799-808. PubMed ID: 30005752
[TBL] [Abstract][Full Text] [Related]
27. The economic evaluation of personalised oncology medicines: ethical challenges.
Lewis JR; Lipworth WL; Kerridge IH; Day RO
Med J Aust; 2013 Oct; 199(7):471-3. PubMed ID: 24099207
[TBL] [Abstract][Full Text] [Related]
28. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
29. A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials.
Nosrati M; Nikfar S; Hasanzad M
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1061-1070. PubMed ID: 35912498
[TBL] [Abstract][Full Text] [Related]
30. Accelerating the delivery of patient-centered, high-quality cancer care.
Abrahams E; Foti M; Kean MA
Clin Cancer Res; 2015 May; 21(10):2263-7. PubMed ID: 25901079
[TBL] [Abstract][Full Text] [Related]
31. Limits to Personalized Cancer Medicine.
Tannock IF; Hickman JA
N Engl J Med; 2016 Sep; 375(13):1289-94. PubMed ID: 27682039
[No Abstract] [Full Text] [Related]
32. Critical Care and Personalized or Precision Medicine: Who needs whom?
Sugeir S; Naylor S
J Crit Care; 2018 Feb; 43():401-405. PubMed ID: 29174462
[TBL] [Abstract][Full Text] [Related]
33. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.
Tsimberidou AM; Ringborg U; Schilsky RL
Am Soc Clin Oncol Educ Book; 2013; ():118-25. PubMed ID: 23714475
[TBL] [Abstract][Full Text] [Related]
34. Personalized medicine in psychiatry: ethical challenges and opportunities.
Evers K
Dialogues Clin Neurosci; 2009; 11(4):427-34. PubMed ID: 20135900
[TBL] [Abstract][Full Text] [Related]
35. Genomic medicine: new frontiers and new challenges.
Pasic MD; Samaan S; Yousef GM
Clin Chem; 2013 Jan; 59(1):158-67. PubMed ID: 23284016
[TBL] [Abstract][Full Text] [Related]
36. Translating genomics in cancer care.
Bombard Y; Bach PB; Offit K
J Natl Compr Canc Netw; 2013 Nov; 11(11):1343-53. PubMed ID: 24225968
[TBL] [Abstract][Full Text] [Related]
37. [Hippocrates and the nineteenth-century French medicine].
Yeo IS
Uisahak; 2003 Dec; 12(2):167-78. PubMed ID: 15005098
[TBL] [Abstract][Full Text] [Related]
38. Personalized medicine in oncology: the future is now.
Schilsky RL
Nat Rev Drug Discov; 2010 May; 9(5):363-6. PubMed ID: 20431568
[TBL] [Abstract][Full Text] [Related]
39. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.
Trosman JR; Weldon CB; Douglas MP; Deverka PA; Watkins JB; Phillips KA
Value Health; 2017 Jan; 20(1):40-46. PubMed ID: 28212967
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
